番茄社区

Balancing aspiration risk with the consequences of medication discontinuation

Addition of GLP-1 drugs led to an even greater reduction

Most are eligible for weight management indication

In the third year, 88% of patients could go 12 weeks or longer with 8-mg dose

SUMMIT trial able to show clinical benefit beyond quality-of-life improvement

Also in TTHealthWatch: frailty as a predictor of dementia

Real-world data suggested semaglutide, liraglutide reduced AUD-related hospitalizations

Also in TTHealthWatch: early sugar exposure, hypertension, and diabetes

Labels now caution about pulmonary aspiration risk

Health news and commentary gathered by 番茄社区 staff

Nearly all participants in SURMOUNT-1 avoided diabetes with the GLP-1/GIP receptor agonist

Diagnoses were also delayed the longer sugar was restricted

Meta-analysis suggests 24-hour clear liquid diet works to avoid aspiration, even with GLP-1s

New guidance replaces earlier rec of a 1-week and 1-day hold of injectable and oral GLP-1 agents